1-8 of 8
Kylie D. Mason, MBBS
Close
Sort by
Journal Articles

Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Luke Coyle, MBBS, FRACP, FRCPA, Nicholas J. Morley, Alessandro Rambaldi, MD, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Gregor Verhoef, MD PhD, Caroline Furness, Rajendra Desai, Noemi Mergen, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-141117
Published: 2020
Journal Articles

More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity

Chia Sharpe, Joanne Davis, PhD, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Dale I Godfrey, PhD, Adam Uldrich, PhD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Rachel Koldej, PhD, David Ritchie, MBChB, PhD FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 4417.
https://doi.org/10.1182/blood-2018-99-117618
Published: 2018
Journal Articles

Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Luke Coyle, Nicholas J. Morley, Alessandro Rambaldi, MD, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Gregor Verhoef, MDPhD, Caroline Furness, Alicia Zhang, A. Scott Jung, Janet L. Franklin
Journal: Blood
Blood (2018) 132 (Supplement 1): 400.
https://doi.org/10.1182/blood-2018-99-112280
Published: 2018
Journal Articles

A Local Experience of Pregnancy Outcomes in Sickle Cell Disease and Red Cell Exchange

Rose Turner, MBBS, Claire Dowsing, Nurse Practitioner, Gemma Crighton, BHB, MBChB, FRACP, FRCPA, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Jeffrey Szer, MBBS
Journal: Blood
Blood (2018) 132 (Supplement 1): 4920.
https://doi.org/10.1182/blood-2018-99-116191
Published: 2018
Journal Articles

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Andrew D. Zelenetz, MD PhD, Gilles A. Salles, Kylie D Mason, MBBS, FRACP, FRCPA, PhD, Carla Casulo, MD, Steven Le Gouill, MD PhD, Laurie H Sehn, MD, Hervé Tilly, MD PhD, Guillaume Cartron, MD PhD, Martine ED Chamuleau, MD, Andre Goy, MD, Constantine S. Tam, MD, Pieternella J Lugtenburg, MD PhD, Rebecca Elstrom, MD, Thalia Farazi, MD PhD, Juan Liu, Edith Szafer-Glusman, PhD, Mehrdad Mobasher, MD, Franck Morschhauser
Journal: Blood
Blood (2016) 128 (22): 3032.
https://doi.org/10.1182/blood.V128.22.3032.3032
Published: 2016
Journal Articles

Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Seong Lin Khaw, MBBS, David C. Huang, MD, PhD, Simon He, MBBS, John F Seymour, MBBS, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Kylie D. Mason, MBBS, PhD, Brenda Chyla, PhD, Elizabeth Litvinovich, MSc, Evelyn McKeegan, PhD, Andrew Krivoshik, MD, PhD, Sari Enschede, MD, Rod Humerickhouse, MD, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2009) 114 (22): 2374.
https://doi.org/10.1182/blood.V114.22.2374.2374
Published: 2009
Journal Articles

The Bcl-2 Protein Family Is Essential for Platelet Survival In Vivo.

Kylie D. Mason, MBBS, Marina R. Carpinelli, PhD, Janelle E. Collinge, PhD, Adrienne A. Hilton, Jamie I. Fletcher, PhD, Andrew W. Roberts, MBBS,PhD, Donald Metcalf, MBBS, David C.S. Huang, MBBS,PhD, Benjamin T. Kile, PhD
Journal: Blood
Blood (2006) 108 (11): 697.
https://doi.org/10.1182/blood.V108.11.697.697
Published: 2006
Journal Articles

Targeting Lymphoid Malignancies with Small Molecule Inhibitors of Pro-Survival Bcl-2 Proteins.

Andrew W. Roberts, MBBS, PhD, Andrew Wei, MBBS, Mark F. van Delft, PhD, Kylie D. Mason, MBBS, Jerry M. Adams, PhD, David C.S. Huang, MBBS, PhD
Journal: Blood
Blood (2005) 106 (11): 1486.
https://doi.org/10.1182/blood.V106.11.1486.1486
Published: 2005